Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 PK Similarity Study (New vs Original Site)
NCT07340476Phase 1Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc. Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity at 43 days. Started Dec 2025; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07340476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340476.